CVKD
Cadrenal Therapeutics, Inc. Common StockNASDAQHealthcare$4.70-1.06%ClosedMarket Cap: $11.0M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
3.39
P/S
0.00
EV/EBITDA
-0.52
DCF Value
$1.72
FCF Yield
-116.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-333.3%
ROA
-305.9%
ROIC
-491.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-3.0M | $-1.37 |
| FY 2025 | $0.00 | $-13.2M | $-6.64 |
| Q3 2025 | $0.00 | $-2.7M | $-1.31 |
| Q2 2025 | $0.00 | $-3.7M | $-1.87 |
Analyst Ratings
View AllHC Wainwright & Co.Buy
2025-05-16Trading Activity
Insider Trades
View AllSzot Matthew Kofficer: Chief Financial Officer
SellWed Dec 31
Golden Lee Scottdirector
SellWed Dec 03
Golden Lee Scottdirector
SellWed Dec 03
Szot Matthew Kofficer: Chief Financial Officer
SellTue Oct 28
Pham Quang Xdirector, 10 percent owner, officer: CEO and Chairman
SellTue Oct 28
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.55
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.